drugset / Trial / NCT02488902
A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum
Phase 2
Completed
521 enrolled
U.S. Army Medical Research and Development Command
SmithKline Beecham · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This was a randomised, double-blind, placebo-controlled study to compare the efficacy of a range four weekly doses of tafenoquine, and weekly mefloquine, with placebo as chemosuppression of P. falciparum malaria. Medications and placebo were matched and a double-dummy technique enabled blinding of tafenoquine versus mefloquine.
Timeline
- Start
- 1998-08
- Primary completion
- 1998-09
- Completion
- 2003-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mefloquine | Unknown | 250 mg | — |
| Subject | Tafenoquine | Small molecule | 25 mg | — |
| Subject | Tafenoquine | Small molecule | 50 mg | — |
| Subject | Tafenoquine | Small molecule | 100 mg | — |
| Subject | Tafenoquine | Small molecule | 200 mg | — |